Immupharma (#IMM) – £0.95m take-up of up to £1.3m broker option at 5p per share
- 2022-08-11 07:57:10
Hello, Share Greeters. One probably goes on a bit too much about one’s long-held belief that a monitor investment in a pocket pharmaceutical venture can reap huge rewards very quickly. At the same time, we must acknowledge that a medical share can fall like a lead anvil from a church tower when, for example, a line of research comes to naught.
Hello Share Sloggers. Fancy investing in another AIM-listed company that is pioneering new medical treatments? Yes, I thought you might be a bit wary. But some of these ventures will come up roses, eventually.
Hello, Share Choosers. As we've often said on this glittering website, investing in small drugs companies is fraught with peril. Cures and remedies take ages to develop, and then you have to steer them through a punishing licence minefield. I’m a great believer, though, in this kind of punt, as the world becomes older and less healthy. And investment in the right pharma could reap big rewards for shareholders, but mainly the sick among us. Today’s suggestion seems a more promising pocket pharma than most.
On the face of it you would think that the daily chart of ImmuPharma represents a classic breakdown over recent months, one which would be a falling knife to catch for all but the most brave of bargain hunters.